1. Home
  2. VTSI vs VERU Comparison

VTSI vs VERU Comparison

Compare VTSI & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VirTra Inc.

VTSI

VirTra Inc.

HOLD

Current Price

$3.02

Market Cap

51.0M

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.61

Market Cap

45.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTSI
VERU
Founded
1993
1971
Country
United States
United States
Employees
N/A
N/A
Industry
Miscellaneous manufacturing industries
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.0M
45.0M
IPO Year
1999
1996

Fundamental Metrics

Financial Performance
Metric
VTSI
VERU
Price
$3.02
$2.61
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
2
Target Price
$5.00
$22.50
AVG Volume (30 Days)
36.2K
260.5K
Earning Date
05-11-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$185,971.00
$16,296,958.00
Revenue This Year
N/A
N/A
Revenue Next Year
$27.30
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.88
$2.05
52 Week High
$6.29
$7.33

Technical Indicators

Market Signals
Indicator
VTSI
VERU
Relative Strength Index (RSI) 44.91 52.75
Support Level $3.02 $2.12
Resistance Level $3.59 $2.67
Average True Range (ATR) 0.18 0.14
MACD -0.00 0.02
Stochastic Oscillator 12.20 54.10

Price Performance

Historical Comparison
VTSI
VERU

About VTSI VirTra Inc.

VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: